TCEB2 plays an essential role in the development of acquired resistance to anti-angiogenic therapy in ovarian cancer cells via suppressing VEGF-A expression and promoting HIF-1α degradation [61]. This evidence concerns the gene VEGFA and ovarian carcinoma.